Creative Biolabs delivers rigorous Lactobacillus casei CRO support for microbiome innovators, LBP developers, and functional food teams. From strain discovery to mechanism-focused performance and manufacturing readiness, we generate decision-grade datasets that help you prioritize candidates, de-risk scale-up variables, and build defensible scientific narratives for research programs.
Trusted workflows, auditable data packages, and strain-level clarity for L. casei programs.
L. casei remains a high-impact research organism because it bridges three priorities in modern microbiome development: robust survivability in product-like conditions, measurable functional outputs in model systems, and scalable manufacturing behavior. Yet “L. casei” is often used loosely, and that ambiguity can undermine comparability, reproducibility, and downstream claims.
A dedicated CRO framework reduces that risk by connecting strain identity, phenotype stability, and process parameters into one coherent evidence trail. This matters especially for the “L. casei group” where genomic relatedness can blur boundaries across closely related taxa if typing depth is insufficient.
L. casei is widely distributed across dairy niches, plant matrices, and host-associated environments. This module isolates strain candidates from relevant sources and applies high-throughput screening for acid tolerance, bile resilience, and adhesion-related traits, building a diversified L. casei strain bank with tractable, data-backed phenotypes.
Accurate identification is non-negotiable for the “L. casei group” (L. casei, L. paracasei, L. rhamnosus), where conventional markers may lack resolution. We combine whole-genome sequencing, MLST/phylogenomics, and phenotype verification to confirm L. casei identity and strengthen traceability for documentation and study comparability.
This module profiles L. casei functional potential using pathogen-competition assays, barrier integrity readouts, and metabolite analytics, then layers in omics when deeper mechanism-of-action (MoA) interpretation is required. The outcome is a defensible map linking L. casei strain behavior to measurable, reproducible research endpoints.
Given the immune-signaling relevance reported for L. casei strains in controlled studies, we use PBMC platforms and epithelial–immune co-culture systems (e.g., Caco-2 with immune cell layers) to quantify cytokine patterns and pathway signatures. This enables selection of L. casei candidates with defined immunomodulatory profiles under standardized conditions.
L. casei performance is tightly coupled to carbohydrate metabolism. We quantify utilization across diverse carbon sources—including prebiotics and human milk oligosaccharide–related motifs—to understand survival advantages and to guide media design. Genotype-to-phenotype links (e.g., operon content) can be incorporated to rationalize L. casei fermentation behavior.
We develop high-density L. casei fermentation strategies by optimizing feed design and key parameters (pH, temperature, dissolved oxygen and redox constraints). Outputs include growth kinetics, yield optimization for viable biomass or defined metabolites, and a scale-aware package that supports smooth translation from lab to pilot runs.
To protect L. casei through processing and shelf life, we evaluate lyoprotectants, drying conditions, and stabilization strategies such as microencapsulation. The deliverable is a formulation blueprint that improves survivability during manufacturing stress and supports stability through simulated gastrointestinal transit—without overpromising outcomes beyond research contexts.
For programs exploring L. casei as a programmable chassis, we apply synthetic biology options for heterologous expression, secretion/display strategies, and targeted genomic edits. Work can include integration design, stability verification, and containment-aware construct planning so engineered L. casei strains remain genetically consistent across passages and experimental runs.
Define L. casei success criteria, endpoints, and sample constraints for decision-grade deliverables.
Isolate or onboard L. casei candidates with traceable provenance and handling controls.
Apply WGS/MLST to verify L. casei and prevent casei-group misclassification.
Run stress, carbohydrate, and functional panels to map L. casei performance ranges.
Optimize L. casei fermentation and stabilization for scale-aware, reproducible outputs.
Provide interpreted datasets, QC documentation, and next-step recommendations for R&D planning.
Clear identity and comparability across L. casei collections and study phases.
Assays connect L. casei signals to pathways, not just surface metrics.
Data links L. casei biology to manufacturability and stability constraints.
Predefined controls reduce variability in L. casei handling and analytics.
Modular testing lets L. casei programs expand without restarting datasets.
Clean documentation supports internal review and partner-facing discussions.
L. casei supports starter culture research for aged cheeses and is widely studied in fermented milk formats, including well-known strain lineages such as Shirota, where performance is evaluated through controlled stability and functionality assays.
L. casei has been evaluated in controlled human studies for endpoints tied to antibiotic-associated diarrhea and bowel regularity, enabling hypothesis-driven biomarker work and strain-to-function comparisons under standardized trial-like parameters.
Specific L. casei strains are studied for effects on NK cell activity, T-cell–linked readouts, and inflammatory signaling balance, supporting mechanistic exploration in immune–epithelial co-culture models and ex vivo profiling designs.
Emerging preclinical research has reported lipid-marker shifts associated with defined L. casei strains (e.g., CAAS36) in hyperlipidemia models, motivating deeper work on metabolite drivers, bile acid interactions, and strain-dependent variability.
L. casei can convert agro-food side streams (fruit residues, whey fractions) into lactic acid in fermentation workflows, supporting sustainability-oriented process R&D and enabling optimization of yields, inhibitor tolerance, and low-cost media strategies.
L. casei is investigated as a microbiome-supporting feed additive and as a silage inoculant component; studies in poultry models also report competitive reductions of enteric pathogen colonization, guiding strain selection for farm-relevant research endpoints.
To support diverse L. casei research, Creative Biolabs offers a curated portfolio of strain-specific products for flexible experimental design.
| Product Name | Catalog No. | Target | Product Overview | Size | Price |
|---|---|---|---|---|---|
| Lactobacillus casei Powder | LBP-005CYG | Lactobacillus | Freeze-dried Lactobacillus casei powder suitable for microbiome and formulation research. | — | Inquiry |
| Lactobacillus casei; L41-1 | LBST-114FG | Lactobacillus | Gram-positive, facultatively anaerobic, non-motile, non-spore-forming rod-shaped bacterium isolated from cream. | 200 µg | $1,156.00 |
| Lactobacillus casei; Y5-2b | LBST-115FG | Lactobacillus | Gram-positive, facultatively anaerobic, non-motile, non-spore-forming rod-shaped L. casei strain. | 200 µg | $1,156.00 |
| Lactobacillus casei; C27 | LBST-116FG | Lactobacillus | L. casei strain isolated from dairy products; Gram-positive, facultatively anaerobic rod-shaped bacterium. | 200 µg | $1,156.00 |
| Lactobacillus casei; 15008 | LBGF-0722-GF90 | Lactobacillus | Dairy-derived L. casei strain with stable phenotypic characteristics for laboratory research. | 200 µg | $1,400.00 |
| Lactobacillus casei DN-114 001 | LBGF-0722-GF93 | Lactobacillus | Well-characterized research strain widely studied for digestive and immune-related biological properties. | 200 µg | $1,250.00 |
| Lactobacillus casei; Dairy products | LBGF-1222-GF6 | Lactobacillus | Recognized L. casei strain derived from dairy products, commonly referenced in microbiome research. | — | Inquiry |
| Lactobacillus casei; Human | LBGF-1222-GF7 | Lactobacillus | L. casei strain (Hansen and Lessel) originally isolated from dairy-associated sources. | — | Inquiry |
| Lactobacillus casei DNA Standard | LBGF-0224-GF3 | Lactobacillus DNA standard | Quantitative DNA standard for assay development, validation, and laboratory quality control. | — | Inquiry |
| Heat inactivated Lactobacillus casei | LBGF-0224-GF37 | Inactivated Lactobacillus | L. casei cells inactivated by heating at 65 °C for 30 minutes, suitable for non-viable studies. | — | Inquiry |
| Lactobacillus casei Genomic DNA | LBGF-0925-GF1114 | Lactobacillus DNA | High-quality purified genomic DNA suitable for PCR, qPCR, and next-generation sequencing applications. | 5 µg | $720.00 |
We confirm L. casei with genome-level methods (WGS plus phylogenomics/MLST) and cross-check phenotype signals. This minimizes taxonomic drift, improves reproducibility, and keeps strain-to-function conclusions defensible across studies.
We profile L. casei across complementary readouts—stress survival, barrier models, metabolite signatures, and antagonism panels—then integrate results to rank candidates. This reduces false positives driven by one assay’s bias.
Yes. L. casei carbohydrate preferences inform media carbon choices, feed strategies, and stability design. When needed, we link utilization phenotypes to genomic loci (operons/transporters) to rationalize performance differences.
We assess integration strategy, confirm genotype by sequencing, track expression consistency, and run passage stability checks. This keeps engineered L. casei behavior consistent, helping teams avoid data drift across long experimental timelines.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.